Aerie Pharmaceuticals, Inc. (AERI) Reaches New 1-Year High at $60.73
Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) reached a new 52-week high on Monday . The stock traded as high as $60.73 and last traded at $60.70, with a volume of 295,267 shares. The stock had previously closed at $58.30.
Several analysts have recently weighed in on AERI shares. Stifel Nicolaus boosted their price target on Aerie Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday, July 4th. Canaccord Genuity set a $56.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 22nd. Mizuho started coverage on Aerie Pharmaceuticals in a report on Wednesday, September 6th. They set a “buy” rating and a $70.00 price target on the stock. ValuEngine upgraded Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, HC Wainwright restated a “buy” rating and set a $69.00 price target on shares of Aerie Pharmaceuticals in a report on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $66.36.
The company’s market cap is $2.20 billion. The company has a 50-day moving average price of $54.57 and a 200-day moving average price of $49.84.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.02. On average, equities research analysts predict that Aerie Pharmaceuticals, Inc. will post ($2.59) EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Teachers Advisors LLC grew its position in shares of Aerie Pharmaceuticals by 23.9% in the 4th quarter. Teachers Advisors LLC now owns 47,324 shares of the company’s stock worth $1,791,000 after buying an additional 9,127 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Aerie Pharmaceuticals by 22.1% in the 1st quarter. Wells Fargo & Company MN now owns 26,273 shares of the company’s stock worth $1,191,000 after buying an additional 4,758 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Aerie Pharmaceuticals by 34.8% in the 1st quarter. Bank of New York Mellon Corp now owns 265,076 shares of the company’s stock worth $12,021,000 after buying an additional 68,360 shares during the last quarter. Swiss National Bank grew its position in shares of Aerie Pharmaceuticals by 8.3% in the 1st quarter. Swiss National Bank now owns 46,800 shares of the company’s stock worth $2,122,000 after buying an additional 3,600 shares during the last quarter. Finally, UBS Asset Management Americas Inc. grew its position in shares of Aerie Pharmaceuticals by 97.3% in the 1st quarter. UBS Asset Management Americas Inc. now owns 12,430 shares of the company’s stock worth $564,000 after buying an additional 6,130 shares during the last quarter. Institutional investors and hedge funds own 94.64% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.